Accretion Pharmaceuticals IPO
Accretion Pharmaceuticals is an NSE SME IPO listed on the NSE SME platform, priced at ₹96–₹101 per share. The stock debuted at ₹79. The IPO had a lot size of ₹1200 shares and a minimum investment of ₹1,21,200.
Accretion Pharmaceuticals Limited IPO
- IPO Dates
- May 14, 2025 – May 16, 2025
- Price band
- ₹96-101 per equity share
- Minimum Investment
- ₹1,21,200
- Issue size
- ₹29.75 Cr
- Lot size
- 1200
- Allotment Date
- May 19, 2025
- Listing
- May 21, 2025
- Listing At
- NSE SME
IPO timeline
-
May 14, 2025
Open Date
Completed
-
May 16, 2025
Close Date
Completed
-
May 19, 2025
Allotment Date
Completed
-
May 21, 2025
Listing Date
Completed
Accretion Pharmaceuticals IPO Essentials
Accretion Pharmaceuticals IPO Details
Accretion Pharmaceuticals IPO is priced at ₹96-101 per share with a total issue size of 29.75 crore. The IPO has a lot size of 1200 shares and is listed on NSE SME.
- Issue price
- ₹96-101 per equity share
- Lot size
- 1200 shares
- Face value
- ₹10 Per Equity Share
- Issue size
- 29,46,000 shares(aggregating up to ₹29.75 Cr)
- Total issue size
- 29,46,000 shares
(aggregating up to ₹29.75 crore) - Fresh issue
- 29,46,000 shares
(aggregating up to ₹29.75 crore) - Listing at
- NSE SME
- List price
- 79.0
- Listing date
- Registrar
- Kfin Technologies Limited
- Lead manager
-
Jawa Capital Services Private Limited
Market Lot Size
Investors can bid for a minimum of 1200 shares and in multiples thereof. The following table depicts the minimum and maximum investment by Retail Investors and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 1200 | ₹1,21,200 |
| Retail(max) | 1 | 1200 | ₹1,21,200 |
| NII (min) | 2 | 2,400 | ₹2,42,400 |
Accretion Pharmaceuticals IPO Analytics
Accretion Pharmaceuticals IPO category-wise subscription trends show day-wise participation across QIB, NII, and retail investors.
Accretion Pharmaceuticals IPO Subscription Status
Accretion Pharmaceuticals IPO subscription status shows demand across retail, NII, and QIB categories, helping investors understand overall participation trends.
The IPO subscription status indicates investor demand across categories.
| As on | QIB / NII | Retail | Total |
|---|---|---|---|
| Shares Offered / Reserved | 1,41,600 / 12,22,800 | 12,22,800 | 25,87,200 |
|
Day 1
14-05-25 06:00 PM
|
(0.00 / 0.51) x | 1.86 x | 1.12 x |
|
Day 2
15-04-25 06:00 PM
|
(0.75 / 0.92) x | 4.01 x | 2.37 x |
|
Day 3
16-05-25 06:00 PM
|
(12.14 / 4.28) x | 10.54 x | 7.67 x |
Accretion Pharmaceuticals Valuations
Earnings
- EPS Pre IPO
- ₹4.74/-
- EPS Post IPO
- ₹6.28/-
- P/E Pre IPO
- 21.29
- P/E Post IPO
- 16.08
Returns
- ROE
- 72.47%
- ROCE
- 36.73%
- RoNW
- 72.47%
- PAT Margin
- 11.51
Fundamentals
- Debt / Equity
- 2.52
- Price / Book
- 7.55
Accretion Pharmaceuticals Financials( In Crs.)
| 31-Dec-24 | 31-Mar-24 | 31-Mar-23 | 31-Mar-22 | |
|---|---|---|---|---|
| Assets | 39.99 | 27.05 | 20.58 | 17.74 |
| Revenue | 35.75 | 33.94 | 29.53 | 22.58 |
| Profit After Tax | 5.24 | 3.88 | 0.10 | 0.08 |
| Net Worth | 13.58 | 5.35 | 3.84 | 3.08 |
| Reserves & Surplus | 5.41 | 1.35 | 0.00 | 0.00 |
| Total Borrowing | 13.79 | 13.48 | 8.47 | 7.61 |
Accretion Pharmaceuticals Company & Offer Insights
About Accretion Pharmaceuticals
Incorporated in 2012, Accretion Pharmaceuticals Limited is a pharmaceutical firm that produces and markets tablets, capsules, and other health care products.
The company provides contract manufacturing services as well. The Company produces and sells Tablets, Capsules, Oral Liquids, External Preparations (Ointment, Cream, Gel, Lotion, Medicated Shampoo, Mouthwash, Dusting Powder), and Oral Powder (Sachet, Dry Syrup).The company is also certified by ISO 9001:2015, ISO 14001:2015, and ISO 22000:2005, demonstrating its commitment towards quality and environmental management systems.
The manufacturing facility of the company is situated in Ahmedabad, Sanand, Gujarat.The company has spread its wings globally, representing itself in over 20 countries, with locations in Africa, Southeast Asia, as well as the Middle East.
Product Portfolio and Services:
Tablets and Capsules – Encompassing antibiotics, anti-inflammatory, pain management, cardiovascular, and gastrointestinal drugs.
Oral Liquids and Syrups – For respiratory, pediatric, and gastrointestinal treatments.
External Preparations – Such as medicated lotions, gels, ointments, and dusting powders for skin treatment and dermatological therapy.
Ayurvedic and Herbal Products – Emphasizing natural wellness remedies for immunity, digestion, and overall health.
As of January 2025, the company has 83 employees (including 4 Executive Directors) on its payroll.
Accretion Pharmaceuticals Promoter(s)
Mr. Mayur Popatlal Sojitra, Mr. Harshad Nanubhai Rathod, Mr. Vivek Ashok Kumar Patel, Mr. Hardik Mukundbhai Prajapati are the company's promoters of Accretion Pharmaceuticals.
Accretion Pharmaceuticals IPO Issue Objectives
- •
- Capital expenditure towards purchase of new equipment/ machineries, etc.
- •
- Capital expenditure towards upgradation of existing manufacturing facility
- •
- Repayment/prepayme nt of certain borrowings availed by the Company
- •
- Funding working capital requirements
- •
- General Corporate Purpose
Contact Information
Contact Details
Accretion Pharmaceuticals
+91-97148 82929
compliance@accretionpharma.com
29 Xcelon Ind Park 1, B/h, Intas Pharmaceuticals, Vasna Chacharvad, Vasna Chacharvadi, Ahmedabad, Sanand, Gujarat,India, 382213
Registrar Contact Details
Kfin Technologies Limited
04067162222, 04079611000
Frequently Asked Questions
Click any question to reveal the answer
Accretion Pharmaceuticals IPO is a book-built IPO worth ₹29.75 crore. The price band is ₹96–₹101 per share. The IPO opens on May 14, 2025 and closes on May 16, 2025. It will be listed on NSE SME Platform. Kfin Technologies Limited is the registrar.
The price band of Accretion Pharmaceuticals IPO is ₹96 to ₹101 per share.
The lot size of Accretion Pharmaceuticals IPO is 1200 shares.
The minimum investment for Accretion Pharmaceuticals IPO is approximately ₹1,21,200 based on the upper price band .
Accretion Pharmaceuticals IPO opens on May 14, 2025 and closes on May 16, 2025.
The allotment date of Accretion Pharmaceuticals IPO is May 19, 2025.
Accretion Pharmaceuticals IPO is expected to be listed on May 21, 2025, on NSE SME Platform.
Accretion Pharmaceuticals IPO valuation snapshot: P/E 16.08, EPS ₹6.28/-, P/B 7.55, RoNW 72.47%, and market cap N/A.
To apply for Accretion Pharmaceuticals IPO, open the IPO Ji app or website, select the IPO, choose your demat account, enter the quantity, and submit the application.
You can check the live subscription status of Accretion Pharmaceuticals IPO on IPO Ji or stock exchange websites. It shows real-time demand across retail, NII, and QIB categories.
Pre-apply allows investors to submit their IPO application before the bidding period starts. The order is placed automatically when the IPO opens.
If you pre-apply for Accretion Pharmaceuticals IPO, your order will be placed when the IPO bidding starts, and a UPI mandate request will be generated.
You can check Accretion Pharmaceuticals IPO allotment status on the registrar or stock exchange websites using your PAN or application number after allotment. You can also check the Accretion Pharmaceuticals IPO allotment status on IPO Ji for quick and easy access.